Crenezumab
Crenezumab is a monoclonal antibody designed for the treatment of Alzheimer's disease. It was developed by the Swiss pharmaceutical company AC Immune and licensed to Genentech, a member of the Roche Group.
Development and Clinical Trials[edit | edit source]
Crenezumab was developed as a potential treatment for Alzheimer's disease, a neurodegenerative disorder characterized by the accumulation of amyloid plaques in the brain. The drug is designed to bind to amyloid-beta proteins, preventing them from aggregating into plaques and promoting their clearance from the brain.
Crenezumab has been evaluated in several clinical trials. In Phase II trials, the drug did not meet its primary endpoints of significantly reducing cognitive decline in patients with mild-to-moderate Alzheimer's disease. However, a trend towards slower cognitive decline was observed in patients with mild Alzheimer's disease, leading to further investigation in this subgroup of patients.
In 2016, a Phase III trial of Crenezumab was initiated in a population of individuals in Colombia who carry a genetic mutation that leads to early-onset Alzheimer's disease. This trial, known as the Alzheimer's Prevention Initiative (API), is a landmark study in the field of Alzheimer's research, as it is the first to test a drug in individuals who are genetically predestined to develop the disease, but who have not yet shown symptoms.
Mechanism of Action[edit | edit source]
Crenezumab is a monoclonal antibody that binds to amyloid-beta proteins. Unlike other antibodies that bind to the same target, Crenezumab is designed to bind to multiple forms of amyloid-beta, including soluble oligomers and insoluble fibrils. This broad-spectrum binding is thought to enhance the drug's ability to prevent plaque formation and promote clearance of amyloid-beta from the brain.
Future Prospects[edit | edit source]
Despite the disappointing results of the Phase II trials, the ongoing API trial represents a significant opportunity for Crenezumab. If the drug is shown to be effective in preventing or delaying the onset of Alzheimer's disease in this high-risk population, it could have major implications for the treatment of Alzheimer's disease worldwide.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
